Contineum Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Contineum Therapeutics, Inc. reported a net loss of $59.978 million for 2025, initiated a Phase 2 trial for PIPE-791 in IPF, and saw its partnered PIPE-307 fail its primary efficacy endpoints in RRMS.
NASDAQ
Contineum Therapeutics files its 10-K report for fiscal year 2024, detailing financial results and providing updates on its clinical development programs, including PIPE-791 and PIPE-307.